RxDoctor Payments Data

Edward Anderson, DO

Cardiovascular Disease · Pinehurst, NCNPI 1700911328

Payments from drug & device makers

$741in general payments, 2019–2025

Across 41 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$225
  • Pfizer$88
  • Abbott$83
  • E.r. Squibb & Sons, L.L.C.$79
  • Amgen$50
  • Boehringer Ingelheim$39
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$741 in reported general payments places this provider in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$226,185
Medicare patients
957
Services billed
4,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban536$504,617
JardianceEmpagliflozin159$160,355
XareltoRivaroxaban85$83,167
EntrestoSacubitril/Valsartan42$46,475
Repatha SureclickEvolocumab50$42,643
MultaqDronedarone Hcl17$11,970
FarxigaDapagliflozin Propanediol13$11,632
Dabigatran EtexilateDabigatran Etexilate Mesylate34$8,801
Praluent PenAlirocumab16$7,829
Isosorbide Dinitrate64$6,847
Ranolazine ErRanolazine104$6,335
Metoprolol Succinate380$4,720
Dofetilide35$4,708
Valsartan123$2,835
Diltiazem 24hr ErDiltiazem Hcl77$2,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$504,617536 claims
Boehringer IngelheimJardiance$39$160,355159 claims
NovartisEntresto$12$46,47542 claims
Sanofi-aventis U.S. LLCMultaq$22$11,97017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →